Related Experiment Video
Updated: Jun 7, 2025
04:36
Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
2.2K
Hemodialysis dose and frequency should be considered in subgroup analysis
Lu Hu1,2, Zhonghua Wang1, Xiang He3
1Department of Cardiology, The First People's Hospital of Chenzhou, Chenzhou, 423000, Hunan, China.
Cardiovascular Diabetology
|November 20, 2024
Summary
New use of SGLT-2 inhibitors in type 2 diabetes patients starting dialysis may lower mortality and major adverse cardiovascular events. However, the study didn't analyze dialysis dose or frequency, potentially impacting results.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are increasingly used in type 2 diabetes (T2DM).
- Their role at dialysis commencement requires further investigation.
- Wang et al. analyzed real-world data on SGLT-2 inhibitor use in T2DM patients initiating dialysis.
Discussion:
- The study found SGLT-2 inhibitor use was linked to reduced all-cause mortality and major adverse cardiovascular events (MACE).
- A median follow-up of 2.0 years was utilized.
- Concerns exist regarding unaddressed confounding factors in subgroup analyses.
Key Insights:
- New SGLT-2 inhibitor use at dialysis initiation is associated with improved long-term outcomes.
- Reduced risk of all-cause mortality and MACE observed.
- Hemodialysis dose and frequency were identified as significant limitations.
Outlook:
- Further research is needed to confirm these findings.
- Investigating the impact of dialysis parameters on SGLT-2 inhibitor efficacy is crucial.
- Optimizing treatment strategies for T2DM patients undergoing dialysis remains a priority.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
64
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
64
01:27Dialysis
269
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
269
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
01:17Factors Affecting Renal Clearance: Renal Impairment
54
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
54
01:22Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
136
The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a...
The pKa of a...
136
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K